Overview
- The White House confirmed a company representative fainted during the televised Oval Office rollout of a GLP-1 drug pricing initiative and is okay after receiving immediate care.
- Initial reports identified the man as Novo Nordisk executive Gordon Findlay, but the company said he was not present; the individual’s identity and medical cause have not been established.
- Dr. Mehmet Oz and the White House Medical Unit assisted as media were escorted out; the event resumed roughly 30 to 60 minutes later, with President Trump saying the man was fine.
- Trump announced agreements with Eli Lilly and Novo Nordisk to lower out-of-pocket costs for GLP-1 medications and to broaden Medicare and Medicaid coverage next year through a new TrumpRx platform.
- Officials and company statements highlighted price targets including projected $149 monthly oral options pending FDA approval and $245 monthly injectables for eligible public-program patients.